中成药治疗成人社区获得性肺炎临床应用指南（2025 版）

ommunity-acquired pneumoniaCAPone of the most common infectious diseasesexhibits increasing morbidity and mortality with ageposing significant clinical challenges. Although Chinese patent medicinesCPMsdemonstrate efficacy in adult CAP treatmenthigh-quality evidence-based guidelines have been lacking. To address this gapwe organized a multidisciplinary expert panel to develop the guideline on treating adult community-acquired pneumonia with Chinese patent medicines2022 Editionadhering to the principles of evidence-basedconsensus-supplementedand experience-referred and following standardized clinical practice guideline development procedures. Through literature review and Delphi questionnairessix clinical questions were identified. Systematic evidence retrieval and synthesis of the best available evidence were conductedintegrating factors such as evidence qualitypatient preferencesvalue orientationsand resource allocation. After two rounds of Delphi surveys and expert consensus meetingsthe guideline was finalized and published in 2023 in Pharmacological Research. This updated edition systematically incorporates recent evidenceadds pharmacoeconomic evaluations and recommendation rationalesand presents 14 recommendations covering nine CPMscovers 9 kinds of traditional Chinese patent medicines. The guideline has been restructured according to the first edition of reporting checklist for Chinese patent medicine guidelinesRIGHT for CPM to enhance clinical applicabilityaccessibilityand operationalizabilitythereby promoting the rational use of CPMs in adult CAP treatment.